Haleon Raises $2.4 Billion: Empowering 170 Years of Trusted Innovation in Everyday Health

Haleon is proud to announce a major milestone in our journey of delivering better everyday health with humanity. Today, we celebrate the successful raising of $2.4 billion in funding—a testament to the trust and belief that investors, partners, and consumers have in our mission. With a legacy spanning over 170 years, Haleon has consistently set the benchmark in quality and innovation, driven by a clear purpose: to enhance everyday health for everyone. Our portfolio of category-leading brands—including Sensodyne, Panadol, Centrum, TUMS, Advil, Otrivin, and Voltaren—stands as a symbol of trusted science combined with deep human understanding. This significant infusion of capital will enable us to further amplify our efforts in making health more inclusive, more accessible, and more sustainable for people around the world. The funds will be strategically deployed to accelerate research and development, enhance our global supply chain, and drive forward digital innovation, ensuring that our trusted brands continue to evolve in a rapidly changing world. We also plan to invest in sustainability initiatives that minimize our environmental footprint, reflecting our commitment to not only provide better health outcomes but to do so responsibly. This announcement marks a pivotal chapter in our company's history, reinforcing our promise to improve lives with every product we offer. As we move ahead with this new growth phase, we remain dedicated to our core values, inspiring confidence that together, we can build a healthier tomorrow. For more updates and insights into our next steps, follow us and join our journey towards a more sustainable and inclusive future in everyday health.